A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
NCT ID: NCT01196208
Last Updated: 2020-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
NCT00848926
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
NCT01026415
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
NCT00947856
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
NCT01492088
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
NCT01461538
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
brentuximab vedotin
Every 21 days by intravenous infusion (1.8 mg/kg)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Completed any previous treatment with radiation, chemotherapy, biologics and/or investigational agents at least 4 weeks prior to the first dose of brentuximab vedotin
Exclusion Criteria
* Known cerebral/meningeal disease
* Peripheral neuropathy of grade 2 or greater
* Females who are pregnant or breastfeeding
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Millennium Pharmaceuticals, Inc.
INDUSTRY
Seagen Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Liga Ulmane, MD
Role: STUDY_DIRECTOR
PSI Company Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford Cancer Center
Stanford, California, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
MD Anderson Cancer Center / University of Texas
Houston, Texas, United States
Peter MacCallum Cancer Center
Melbourne, , Australia
Leuven University Hospital
Leuven, , Belgium
Specializirana bolnica aktivno lechenie detsa ohcohematologichni zabolyavania Hematologichno
Sofia, , Bulgaria
Specializirana bolnica za aktivno lechenie na hematologichni zabolyavania
Sofia, , Bulgaria
Hopital Saint-Louis/Service d'Hematologie
Paris, Cedex 10, France
South Lyon Hospital Center, Department of Dermatology
Lyon, , France
Centre Henri Becquerel / Centre Regional de Lutte Contre le Cancer
Rouen, , France
Johannes Wesling Hospital Minden, Department of Dermatology
Minden, , Germany
Szent Istvan es Szent Laszlo Korhaz Rendelointezet Haematologiai es Ossejt-transzplantacios osztaly
Budapest, , Hungary
Debreceni Egyetem Orvos és Egeszsegtudomanyi Centrum, III. sz. Belgyogyaszati Klinika
Debrecen, , Hungary
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikat Kozpont
Szeged, , Hungary
Polyclinic S. Orsola-Malpighi, Institute of Hematology and Medical Oncology "Lorenzo and Ariosto Seragnoli"
Bologna, , Italy
IRCCS University Hospital San Martino
Genoa, , Italy
Klinika Hematologii, Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi
Lodz, , Poland
Klinika Hematologii, Instytut Hematologii i Transfuzjologii
Warsaw, , Poland
Centrum Onkologii Institut im. Marii Sklodowskiej-Curie
Warsaw, , Poland
Spitalul Clinic Judetean de Urgenta Targu Mures, Sectia Clinica Hematologie si Transplant Medular
Târgu Mureş, Mureș County, Romania
Fundeni Clinical Institute, Center for Hematology and Bone Marrow Transplantation
Bucharest, , Romania
Institutul Clinic Fundeni, Centrul de Hematologie si Transplant Medular Stefan Berceanu
Bucharest, , Romania
Rossijskij onkologicheskij nauchnyj centr im. N.N. Blokhina RAMN
Moscow, , Russia
Gematologicheskj nauchnyj centr RAMN
Moscow, , Russia
Research Institute of Clinical Immunology
Novosibirsk, , Russia
Sankt-Peterburgskij gosudarstvennyj medicinskij universitet im. akademika I. P. Pavlova
Saint Petersburg, , Russia
Clinical Center of Serbia, Clinic of Hematology
Belgrade, , Serbia
University Hospital 12 de Octubre, Department of Dermatology
Madrid, , Spain
University Hospital Zurich, Department of Dermatology
Zurich, , Switzerland
Queen Elizabeth Hospital
Birmingham, , United Kingdom
St John's Institute of Dermatology
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-020363-21
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
SGN35-010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.